ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds for Solid Tumors Are to be Reported at ASCO.CAMBRIDGE, Mass. -- ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, today announced that clinical findings for three different TAP compounds for the treatment of solid tumors are to be reported to be spoken of; to be mentioned, whether favorably or unfavorably. See also: Report at the 43rd American Society of Clinical Oncology American Society of Clinical Oncology, or ASCO, is an organization that represents all clinical oncologists. Every year, ASCO holds a large symposium where physicians and researchers meet to convey and discuss research and ideas. (ASCO ASCO American Society of Clinical Oncology ASCO Association of Schools and Colleges of Optometry (since 1941; Rockville, Maryland) ASCO Australian Standard Classification of Occupations ASCO Automatic Switch Company ) Annual Meeting to take place June 1-5, 2007 in Chicago, IL. Trastuzumab-DM1 (abstract #1042) "A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate conjugate /con·ju·gate/ (kon´jdbobr-gat) 1. paired, or equally coupled; working in unison. 2. a conjugate diameter of the pelvic inlet; used alone usually to denote the true conjugate diameter; see (ADC (1) See A/D converter. (2) (Apple Display Connector) A peripheral connector from Apple that combines digital video display, USB and power in one cable. ), in patients (pts) with HER2+ metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. breast cancer (BC)." * Saturday, June 2, 2:00-6:00 pm: Breast Cancer - Metastatic General Poster Session (poster #G4). * Trastuzumab-DM1 is in development by Genentech. HuC242-DM4 (abstract #3062) "A phase I study of a CanAg-targeted immunoconjugate, huC242-DM4, in patients with Can Ag-expressing solid tumors." * Sunday, June 3, 8:00 am-12:00 noon: Developmental Therapeutics: Immunotherapy General Poster Session (poster #F14). * HuC242-DM4 is wholly owned by ImmunoGen. HuN901-DM1 (abstract #18084) "Phase II trial of huN901-DM1 in patients with relapsed small cell lung cancer Lung Cancer, Small Cell Definition Small cell lung cancer is a disease in which the cells of the lung tissues grow uncontrollably and form tumors. Description Lung cancer is divided into two main types: small cell and non-small cell. (SCLC SCLC abbr. Southern Christian Leadership Conference ) and CD56-positive small cell carcinoma small cell carcinoma n. See oat cell carcinoma. small cell carcinoma Small cell undifferentiated carcinoma, undifferentiated carcinoma A highly aggressive malignancy, usually of lung, which arises in proximal bronchi ." * To be published as abstract in the Journal of Clinical Oncology The Journal of Clinical Oncology is a medical journal published by the American Society of Clinical Oncology. The Journal was founded in 1983 and publishes original research and review articles on topics relating to cancer. It is published 3 times a month. . * HuN901-DM1 is wholly owned by ImmunoGen. About ImmunoGen's TAP Technology ImmunoGen created its TAP technology to enhance the anticancer activity of tumor-targeting antibodies while maintaining a favorable tolerability profile. The Company attaches to an antibody one of ImmunoGen's proprietary cell-killing agents. The antibody serves to deliver the agent specifically to cancer cells and the agent serves to kill the cancer cells. The agent is attached using one of the Company's "linkers." ImmunoGen has developed alternative cell-killing agents and linkers so the best product design can be achieved for each antibody and its target. ImmunoGen uses its cell-killing agents with its wholly-owned antibodies to create its own anticancer compounds, and also outlicenses its technology for use by other companies with their proprietary antibodies. Companies licensing the right to develop anticancer compounds to specific targets using ImmunoGen's TAP technology include Biogen Idec, Biotest AG, Centocor (Johnson & Johnson), Genentech, and sanofi-aventis. Four TAP compounds are already in clinical testing - huN901-DM1 and huC242-DM4, in development by ImmunoGen, trastuzumab-DM1, in development by Genentech, and AVE9633, in development by sanofi-aventis. ImmunoGen expects its collaborators to advance two additional TAP compounds into clinical testing in 2007. About ImmunoGen, Inc. ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company's proprietary TAP technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. Two TAP compounds wholly owned by ImmunoGen are in clinical testing - huN901-DM1 and huC242-DM4. Three anticancer compounds are in clinical testing through ImmunoGen's collaborations with other companies - AVE9633 and AVE1642, in development by sanofi-aventis, and trastuzumab-DM1, in development by Genentech. Multiple compounds are in research/preclinical development. This press release includes forward-looking statements based on management's current expectations. For these statements, ImmunoGen claims the protection of the safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. for forward-looking statements provided by the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Various factors could cause the Company's actual results to differ materially from those discussed or implied in the forward-looking statements and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this release. Factors that could cause future results to differ materially from such expectations include, but are not limited to: the outcome of the Company's research and clinical development processes; the outcome of the Company's collaboration partners' research and clinical development processes; the difficulties inherent in the development of novel pharmaceuticals, including uncertainties as to the timing, expense and results of preclinical studies and clinical trials; the Company's dependence on collaborative partners; and other factors more fully described in ImmunoGen's Annual Report on Form 10-K for the fiscal year ended June 30, 2006 and other reports filed with the Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion